DexCom (DXCM) Competitors

DexCom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk.

Do analysts recommend DXCM or MDT?

DexCom currently has a consensus price target of $99.00, indicating a potential upside of 38.69%. Medtronic has a consensus price target of $96.14, indicating a potential upside of 13.64%. Given DexCom's stronger consensus rating and higher possible upside, research analysts plainly believe DexCom is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.95
Medtronic	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.44

Does the media favor DXCM or MDT?

In the previous week, Medtronic had 40 more articles in the media than DexCom. MarketBeat recorded 61 mentions for Medtronic and 21 mentions for DexCom. DexCom's average media sentiment score of 1.54 beat Medtronic's score of 1.03 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	18 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Medtronic	39 Very Positive mention(s)	5 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor DXCM or MDT?

Medtronic received 607 more outperform votes than DexCom when rated by MarketBeat users. Likewise, 75.45% of users gave Medtronic an outperform vote while only 71.78% of users gave DexCom an outperform vote.

Company	Underperform	Outperform
DexCom	Outperform Votes 982 71.78%	Underperform Votes 386 28.22%
Medtronic	Outperform Votes 1589 75.45%	Underperform Votes 517 24.55%

Do insiders and institutionals have more ownership in DXCM or MDT?

97.8% of DexCom shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 0.2% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, DXCM or MDT?

DexCom has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Is DXCM or MDT more profitable?

DexCom has a net margin of 14.29% compared to Medtronic's net margin of 12.83%. DexCom's return on equity of 30.14% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	14.29%	30.14%	10.11%
Medtronic	12.83%	14.07%	7.70%

Which has better earnings & valuation, DXCM or MDT?

Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.03B	6.94	$576.20M	$1.43	49.92
Medtronic	$33.20B	3.27	$3.68B	$3.29	25.71

Summary

DexCom beats Medtronic on 13 of the 19 factors compared between the two stocks.